Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Boundless Bio Inc. (BOLD – Research Report), retaining the price target of $15.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andrew Berens has given his Buy rating due to a combination of factors including the promising developments in Boundless Bio Inc.’s pipeline. The company is on track with its clinical programs, particularly the BBI-355 (CHK1) trial, which is expected to deliver significant proof-of-concept data in the second half of 2025. This data will include results from both single agent and combination dose escalation studies, with the potential for improved objective response rates in patients with specific genetic amplifications.
Furthermore, the use of the ECHO diagnostic tool to assess ecDNA’s role in treatment response adds a novel dimension to the trial’s insights. The company’s financial position is also strong, with sufficient cash reserves projected to support operations into 2027. These factors collectively suggest a positive outlook for the company’s stock, justifying the Buy rating.